Background: One of the suggested mechanisms of increased cardiovascular risk in postmenopause is a loss of the antioxidant effects of estrogens. It has been shown that classical cardiovascular risk factors increase oxidative stress on the arterial wall, and that endothelial cells react to this insult by increased expression of cellular adhesion molecules (CAM), which in turn are markers of arterial wall inflammation. Methods: A randomized, placebo-controlled, double-blind study was performed in 60 postmenopausal women with high cardiovascular risk profiles, but free from clinical atherosclerotic disease. Patients were randomized to either antioxidant supplementation (using a combination of natural antioxidants; n = 30) or placebo (n = 30), and followed for 12 weeks. The concentrations of the adhesion molecules sVCAM-1 and sICAM-1 were measured by ELISA at baseline and at the end of the study, as well as total cholesterol, LDL, HDL, triglycerides and blood pressure. Results: 27 women in the antioxidant supplementation group and 29 on placebo completed the study. At baseline, there were no significant differences in measured parameters between the groups: sICAM-1 concentrations were 341.8 ± 116.9 vs. 349.9 ± 104.6 ng/ml (active treatment vs. placebo; p = n.s.) and sVCAM-1 concentrations were 780.5 ± 325.8 vs. 761.0 ± 333.7 ng/ml (p = n.s.). In contrast, at the end of the study, sICAM-1 concentrations were 301.6 ± 56.0 vs. 356.0 ± 134.8 ng/ml (active treatment vs. placebo; p = 0.053) and sVCAM-1 concentrations were 656.0 ± 326.5 vs. 818.5 ± 381.0 ng/ml (p = 0.04). There were no significant differences between or changes within the groups in measured cholesterol and blood pressure. Conclusion: Antioxidant supplementation reduces serum concentrations of endothelium-derived adhesion molecules sICAM-1and sVCAM-1 in postmenopausal women with high cardiovascular risk profiles.

Keywords:
Adhesion molecules, Antioxidants, Cardiovascular risk, Postmenopausal women
1.
Grundy SM, Bazzarre T, Cleeman J, D’Agostino RB Sr, Hill M, Houston-Miller N, Kannel WB, Krauss R, Krumholz HM, Lauer RM, Ockene IS, Pasternak RC, Pearson T, Ridker PM, Wood D: Prevention Conference V: Beyond secondary prevention: Identifying the high risk patient for primary prevention. Writing Group I. Circulation; 2000:101:E3–E11.
2.
Ross R: Atherosclerosis – an inflammatory disease. N Engl J Med 1999;340:115–126.
3.
Berliner JA, Navab M, Fogelman A, et al: Atherosclerosis basic mechanisms. Oxidation, inflammation and genetics. Circulation 1995;91:2488–2496.
4.
Alexander RW: Hypertension and the pathogenesis of atherosclerosis. Oxidative stress and the mediation of the arterial inflammatory response: A new perspective. Hypertension 1995;25:155–161.
5.
Colins T: Endothelial nuclear factor κB and initiation of the atherosclerotic lesion. Lab Invest 1993:68:499–508.
6.
Marui N, Offermann MK, Swerlick R, Kunsch C, Rosen CA, Ahmad M, et al: Vascular cell adhesion molecule-1 (VCAM-1) gene transcription and expression are regulated through an antioxidant-sensitive mechanism in human vascular endothelial cells. J Clin Invest 1993;92:1866–1874.
7.
Gerszten RE, Lim YC, Ding HT, Snapp K, Kansas G, Dichek DA, et al: Adhesion of monocytes to vascular cell adhesion molecule-1-transduced human endothelial cells: Implication for atherogenesis. Circ Res 1998;82:871–878.
8.
Hackman A, Abe Y, Insull W, Pownall H, Smith L, Dunn K, et al: Levels of soluble cell adhesion molecules in patients with dyslipidemia. Circulation 1996;93:1334–1338.
9.
Rohde LE, Hennekens CH, Ridker PM: Cross-sectional study of soluble intercellular adhesion molecule-1 and cardiovascular risk factors in apparently healthy men. Arterioscler Thromb Vasc Biol 1999;19:1595–1599.
10.
Hwang S, Ballantyne C, Sharrett AR, Smith L, Davis C, et al: Circulating adhesion molecules VCAM-1, ICAM-1 and E-selectin in carotid atherosclerosis and incident coronary heart disease cases. The Atherosclerosis Risk in Communities (ARIC) Study. Circulation 1997;96:4219–4225.
11.
Schwenke DC: Aging, menopause, and free radicals. Semin Reprod Endocrinol 1998;16:281–308.
12.
Martin C, Barturen K, Martinez R, Lacort M, Ruiz-Larrea MB: In vitro inhibition by estrogens of the oxidative modifications of human lipoproteins. J Physiol Biochem 1998;54:195–202.
13.
Kushi LH, Folsom AR, Prineas RJ, Mink PJ, Wu Y, Bostick RM: Dietary antioxidant vitamins and death from coronary heart disease in postmenopausal women. N Engl J Med 1996;334:1156–1161.
14.
Steinberg D: Antioxidant vitamins and coronary heart disease. N Engl J Med 1993;328:1487–1488.
15.
Caulin-Glaser T, Farrell W, Pfau S, Zaret B, Bunger K, Setaro , et al: Modulation of circulating cellular adhesion molecules in postmenopausal women with coronary artery disease. J Am Coll Cardiol 1998;31:1555–1560.
16.
Van Baal MW, Emeis JJ, Kemenans P, Kessel H, Peters-Muller ERA, Schalkwijk CG, et al: Short-term hormone replacement therapy: Reduced plasma levels of soluble adhesion molecules. Eur J Clin Invest 1999;29:913–921.
17.
Koh KK, Blum A, Hathaway L, Mincemoyer R, Csako G, Waclawiw M et al: Vascular effects of estrogen and vitamin E therapies in postmenopausal women. Circulation 1999;100:1851–1857.
18.
Koh KK, Cardilo C, Bui M., Hathaway L, Csako G, Waclawiw M, et al: Vascular effects of estrogen and cholesterol lowering therapies in hypercholesterolemic women. Circulation 1999;99:354–360.
19.
Task Force Report: Prevention of coronary heart disease in clinical practice. Eur Heart J 1998;19:1434–1503.
20.
Key RA: Microalgae as food and supplement. Crit Rev Food Sci Nutr 1991;30:555–573.
21.
Packer L, Rimbach, Virgili F: Antioxidant activity and biologic properties of a procyanidin-rich extract from pine (Pinus maritima) bark, pycnogenol. Free Radic Biol Med 1999;27:704–724.
22.
Fitzpatrik DF, Bing B, Rohdewald P: Endothelium-dependent vascular effects of pycnogenol. J Cardiovasc Pharmacol 1998;32:509–515.
23.
Pietri S, Maurelli E, Drieu K, Culcasi M: Cardioprotective and anti-oxidant effects of the terpenoid constituents of Ginkgo biloba extract (EGb 761). J Mol Cell Cardiol 1997;27:733–742.
24.
Seljeflot I, Arnesen H, Brudet IR, Nenseter MS, Drevont CA, Hjermann I: Effects of omega-3 fatty acids and/or antioxidants on endothelial cell markers. Eur J Clin Invest 1998;28:629–635.
25.
Chalmers C: The antioxidants and cardiovascular disease. Why do we still not have the answers. Ann Intern Med 1995;123:887.
26.
Ridker PM, Hennekens CH, Roitmen-Jonson B, Stampfer MJ, Allen J: Plasma concentration of soluble intercellular adhesion molecule 1 and risk of future myocardial infarction in apparenly healthy men. Lancet 1998;351:88–92.
27.
Ridker P, Hennekens Ch, Buring J, Rifai N: C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med 2000;342:836–843.
28.
Rohde LE, Lee RT, Rivero J, Jamacochian M, Arroyo LH, Briggs M: Circulating cell adhesion molecules are correlated with ultrasound-based assessment of carotid atherosclerosis. Arterioscler Thromb Vasc Biol 1998;18:1765–1770.
29.
De Cateriana R, Basta G, Lazzerini G, Dell’Omo G, Petrucci R, Morale M, et al: Soluble vascular adhesion molecule-1 as a biohumoral correlate of atherosclerosis. Arterioscler Thromb Vasc Biol 1997;17:2646–2654.
30.
Gimbrone MAJ, Bevilacqua MP, Cybulsky MI: Endothelial-dependent mechanisms of leukocyte adhesion in inflammation and atherosclerosis. Ann NY Acad Sci 1990;598:77–85.
31.
Steinberg D, Parthasarathy S, Carew TE, et al: Beyond cholesterol. Modifications of low-density lipoprotein that increase its atherogenicity. N Engl J Med 1989;320:915–924.
32.
Lehr HA, Hubner C, Nolte D, Finckh B, Beisiegel U, Kohlschutter A, Messmer K: Oxidatively modified human low-density lipoprotein stimulates leukocyte adherence to the microvascular endothelium in vivo. Res Exp Med (Berlin) 1991;191:85–90.
33.
Khan BV, Parthasarathy SS, Alexander RW, Medford RM: Modified low density lipoprotein and its constituents augment cytokine-activated vascular cell adhesion molecule-1 gene expression in human vascular endothelial cells. J Clin Invest 1995;95:1262–1270.
34.
Kume N, Gimbrone MA Jr: Lysophosphatidylcholine transcriptionally induces growth factor gene expression in cultured human endothelial cells. J Clin Invest 1994;93:907–911.
35.
Kume N, Cybulsky MI, Gimbrone MA Jr: Lysophosphatidylcholine, a component of atherogenic lipoproteins, induces mononuclear leukocyte adhesion molecules in cultured human and rabbit arterial endothelial cells. J Clin Invest 1992;90:1138–1144.
36.
Weber C, Erl W, Pietsch A, Strobel M, Ziegler-Heitbrock HW, Weber PC: Antioxidants inhibit monocyte adhesion by suppressing nuclear factor-kappa B mobilization and induction of vascular cell adhesion molecule-1 in endothelial cells stimulated to generate radicals. Arterioscler Thromb 1994;14:1665–1673.
37.
Cleland JGF, Krikler DM: Modification of atherosclerosis by agents that do not lower cholesterol. Br Heart J 1993;69(suppl):54–62.
38.
Stephens NG, Parsons A, Schofield PM, Kelly F, Cheeseman K, Mitchison MJ: Randomized control trial of vitamin E in patients with coronary heart disease: Cambridge Heart Antioxidant Study (CHAOS). Lancet 1996;347:781–786.
39.
The Heart Outcome Prevention Evaluation study investigators: Vitamin E supplementation and cardiovascular risk events in high risk patients. N Engl J Med 2000;342:154–160.
40.
Halliwell B: The antioxidant paradox. Lancet 2000;355:1179–1180.
41.
Goudev A, Georgiev D, Kyurkchiev S, Ganev V, Kehayov I: Still life in oxidation hypothesis of atherogenesis (letter). Lancet 2000;356:165–166.
© 2001 S. Karger AG, Basel
2001
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.